Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 647-653

  Mauri, Francesco A ^a   Pinato, David J ^a,b   Trivedi, Pritesh ^a   Sharma, Rohini ^a   Shiner, Robert J ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chemokine; CX3CL1; CX3CR1; Fractalkine; Lung cancer; Metastasis

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LARGE CELL NEUROENDOCRINE CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR MODEL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN METASTASIS; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CX3CL1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, CHEMOKINE; TISSUE ARRAY ANALYSIS;

EID: 84863456279     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1818     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Cersosimo RJ: Lung cancer: a review. Am J Health Syst Pharm 59: 611-642, 2002.
3. Fry WA, Phillips JL and Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86: 1867-1876, 1999. (Pubitemid 29513058)
4. Sawaya R: Considerations in the diagnosis and management of brain metastases. Oncology (Williston Park) 15: 1144-1165, 2001.
5. Langley RR and Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321, 2007. (Pubitemid 46984829)
6. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
7. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM and Keane MP: CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 1028: 351-360, 2004. (Pubitemid 40361836)
8. Singh S, Sadanandam A and Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26: 453-467, 2007. (Pubitemid 350115099)
9. Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11: 597-606, 2011.
10. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686, 2003. (Pubitemid 36760683)
11. Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105: 186-189, 2003.
12. Marchesi F, Piemonti L, Fedele G, et al: The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68: 9060-9069, 2008.
13. Andre F, Cabioglu N, Assi H, et al: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17: 945-951, 2006. (Pubitemid 43778984)
14. Marshall HM, Leong SC, Bowman RV, Yang IA and Fong KM: The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. Respirology 17: 247-260, 2012.
15. Dhillon T, Mauri FA, Bellezza G, et al: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 5: 314-319, 2010.
16. Shi SR, Key ME and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
17. Andreasson U, Ek S, Merz H, et al: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett 259: 138-145, 2008. (Pubitemid 350251646)
18. White ES, Flaherty KR, Carskadon S, et al: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9: 853-860, 2003. (Pubitemid 36182624)
19. Burger M, Glodek A, Hartmann T, et al: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22: 8093-8101, 2003. (Pubitemid 37487300)
20. Hartmann TN, Burger JA, Glodek A, Fujii N and Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24: 4462-4471, 2005. (Pubitemid 40961769)
21. Raynaud CM, Mercier O, Dartevelle P, et al: Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. Clin Lung Cancer 11: 187-191, 2010.
22. Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698, 2004. (Pubitemid 38924507)
23. Kim M, Rooper L, Xie J, Kajdacsy-Balla AA and Barbolina MV: Fractalkine receptor CX3CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res 10: 11-24, 2012.
24. Matsubara T, Ono T, Yamanoi A, Tachibana M and Nagasue N: Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 95: 241-249, 2007.
25. Jubb AM, Cesario A, Ferguson M, et al: Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer 104: 1877-1881, 2011.
26. +) chemokines in non-small cell lung cancer. PLoS One 6: e14593, 2011.
27. Mizuno T, Kawanokuchi J, Numata K and Suzumura A: Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979: 65-70, 2003. (Pubitemid 36798062)
28. Hurst LA, Bunning RA, Couraud PO, et al: Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol 210: 108-112, 2009.
29. Imaizumi T, Yoshida H and Satoh K: Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 11: 15-21, 2004.
30. Nevo I, Sagi-Assif O, Meshel T, et al: The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 273: 127-139, 2009.
31. Yamazaki K, Sugio K, Yamanaka T, et al: Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. Anticancer Res 30: 1311-1315, 2010.
32. Lee SJ, Namkoong S, Kim YM, et al: Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291: H2836-H2846, 2006. (Pubitemid 44904084)
33. Oh Y, Taylor S, Bekele BN, et al: Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 115: 2930-2938, 2009.
34. Mamon HJ, Yeap BY, Janne PA, et al: High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23: 1530-1537, 2005.
35. Chen AM, Jahan TM, Jablons DM, Garcia J and Larson DA: Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 109: 1668-1675, 2007. (Pubitemid 46595704)
36. Simon GR and Turrisi A: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: S324-S339, 2007.
37. Besse B, Massard C, Haddad V, et al: ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann Oncol 22: 575-581, 2011.
38. D'Haese JG, Demir IE, Friess H and Ceyhan GO: Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 14: 207-219, 2010.